The global interventional oncology market size was estimated at USD 2.90 billion in 2025 and is projected to reach USD 5.61 billion by 2033, growing at a CAGR of 8.59% from 2026 to 2033. This steady expansion is primarily driven by the increasing prevalence of cancer worldwide, continuous technological advancements in minimally invasive treatment procedures, and the growing geriatric population that is more susceptible to chronic diseases such as cancer. In addition, the rising emphasis on early cancer detection and diagnosis, along with increasing public and private investments aimed at improving oncology care infrastructure and treatment accessibility, is further supporting market growth. Healthcare systems and research institutions are actively focusing on developing innovative interventional oncology solutions that enhance treatment precision, improve clinical outcomes, and reduce hospitalization time, thereby contributing significantly to the overall expansion of the market.

There has been a substantial increase in the number of cancer cases globally, which has created a strong demand for advanced treatment solutions capable of delivering more effective and patient-friendly cancer care. According to the World Health Organization (WHO), approximately 20 million new cancer cases and 9.7 million cancer-related deaths were recorded worldwide in 2022. By 2050, global cancer cases are expected to exceed 35 million, representing a 77% rise in the overall cancer burden. Interventional oncology plays a critical role in addressing this growing challenge by offering a range of minimally invasive treatment techniques, including radiofrequency ablation (RFA), transarterial chemoembolization (TACE), and cryoablation. These procedures provide notable advantages over conventional surgical approaches, such as shorter recovery periods, reduced hospital stays, minimized complications, and improved patient comfort. As cancer incidence continues to increase globally, the adoption of these advanced interventional techniques is anticipated to grow rapidly due to their ability to enhance survival rates while maintaining patients’ quality of life.

The rising global incidence of cancer is largely linked to lifestyle and environmental risk factors, including increased tobacco consumption, unhealthy dietary habits, excessive alcohol intake, growing levels of air pollution, and physical inactivity. This escalating disease burden presents significant challenges for healthcare systems worldwide, prompting the need for more efficient, targeted, and less invasive treatment solutions. Interventional oncology has emerged as an increasingly preferred alternative to traditional cancer treatments such as open surgery, radiation therapy, and systemic chemotherapy. By enabling precise tumor targeting with minimal damage to surrounding healthy tissues, these procedures help reduce patient trauma, shorten recovery timelines, and improve treatment tolerability. These clinical and operational advantages are key contributors to the growing acceptance of interventional oncology procedures among healthcare providers and patients, thereby driving sustained growth in the market.

Key Market Trends & Insights:

• North America’s interventional oncology devices market held the largest share of 41.80% of the global market in 2025, reflecting the region’s strong healthcare infrastructure, high adoption of advanced medical technologies, and well-established oncology treatment ecosystem. The presence of leading medical device manufacturers, increased awareness regarding minimally invasive cancer treatments, and favorable reimbursement policies have significantly supported market expansion across the region. In addition, the growing prevalence of cancer, coupled with continuous investments in research and development activities, has encouraged healthcare providers to adopt innovative interventional oncology solutions. The availability of skilled healthcare professionals and advanced diagnostic capabilities has further strengthened North America’s leadership position in the global market.

• The U.S. interventional oncology market is anticipated to witness lucrative growth over the forecast period, driven by increasing cancer incidence, rising demand for minimally invasive treatment options, and strong technological innovation within the healthcare sector. Growing patient preference for procedures that offer reduced recovery time and fewer complications is accelerating the adoption of interventional oncology techniques across hospitals and specialty clinics. Furthermore, ongoing clinical research, supportive regulatory frameworks, and increasing collaborations between healthcare institutions and device manufacturers are expected to create significant growth opportunities in the country’s market landscape.

• By technique, the ablation therapies segment dominated the market in 2025 with the largest revenue share, primarily due to its effectiveness in treating tumors through minimally invasive approaches. Ablation procedures, including radiofrequency ablation, microwave ablation, and cryoablation, enable precise tumor targeting while minimizing damage to surrounding healthy tissues. These therapies are increasingly preferred for patients who are not suitable candidates for traditional surgery, as they offer shorter hospital stays, lower complication risks, and faster recovery. Continuous technological improvements and expanding clinical applications across multiple cancer types have further strengthened the adoption of ablation therapies globally.

• By procedures, the vascular intervention segment held a leading market share of 38.1% in 2025, supported by the growing utilization of image-guided techniques for targeted cancer treatment. Vascular interventions, such as transarterial chemoembolization (TACE) and radioembolization, allow physicians to deliver therapeutic agents directly to tumors through blood vessels, enhancing treatment effectiveness while reducing systemic side effects. The increasing preference for localized therapies that improve precision and patient outcomes has contributed significantly to the expansion of this segment. Advancements in imaging technologies and catheter-based delivery systems have also played a vital role in strengthening procedural efficiency and clinical success rates.

• By application, the liver cancer segment accounted for the largest revenue share of 27.8% in 2025, largely due to the high global prevalence of liver malignancies and the effectiveness of interventional oncology techniques in treating hepatic tumors. Minimally invasive procedures are widely used for liver cancer management, especially in cases where surgical resection is not feasible. Techniques such as ablation and embolization provide targeted treatment options that help control tumor progression while preserving liver function. Increasing awareness regarding early diagnosis, along with growing adoption of image-guided therapies for liver cancer treatment, continues to drive strong demand within this application segment.

Order a free sample PDF of the Interventional Oncology Market Intelligence Study, published by Grand View Research.

Market Size & Forecast:

• 2025 Market Size: USD 2.90 Billion

• 2033 Projected Market Size: USD 5.61 Billion

• CAGR (2026-2033): 8.59%

• North America: Largest market in 2025

• Asia Pacific: Fastest growing market

Key Companies & Market Share Insights:

Key players operating in the interventional oncology market are actively undertaking a wide range of strategic initiatives to strengthen their market presence and expand the reach of their products and services across global healthcare systems. Companies are increasingly focusing on enhancing their product portfolios, improving technological capabilities, and expanding their geographic footprint to address the growing demand for minimally invasive cancer treatment solutions. These efforts are aimed at gaining a competitive advantage while meeting the evolving needs of healthcare providers and patients seeking more effective and efficient oncology treatments.

Strategies such as expansion activities and partnerships are playing a key role in propelling market growth. Market participants are investing in the establishment of new manufacturing facilities, research centers, and distribution networks to improve product accessibility and operational efficiency. At the same time, collaborations with hospitals, research institutions, and technology providers are enabling companies to accelerate innovation, develop advanced interventional oncology devices, and enhance clinical outcomes. Strategic partnerships also support knowledge sharing, regulatory approvals, and faster commercialization of new technologies, ultimately contributing to the overall advancement and growth of the interventional oncology market.

Key Players

• Medtronic plc

• Boston Scientific Corporation

• Johnson & Johnson (Ethicon)

• Teleflex Incorporated

• Cook Medical

• AngioDynamics Inc.

• Stryker Corporation

• Profound Medical

• Terumo Corporation

• Siemens Healthineers

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion:

The interventional oncology market is experiencing strong growth driven by the rising global burden of cancer and the increasing demand for minimally invasive treatment options. Advancements in image-guided technologies and ablation techniques are transforming cancer care by enabling more precise tumor targeting, improved clinical outcomes, and faster patient recovery compared to conventional treatment approaches. Growing awareness of early cancer detection, expanding healthcare investments, and the increasing aging population are further supporting market expansion.